Results 11 to 20 of about 178,774 (332)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Pharmaceuticals, 2020
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA.
Yusuke Funakoshi, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Yutaka Fujioka, Kosuke Takigawa, Masahiro Mizoguchi   +7 more
doaj   +1 more source

Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits [PDF]

, 2017
Our objective was to assess overall survival of cervical cancer patients following prior platinum/bevacizumab chemotherapy, comparing retreatment with platinum/bevacizumab with alternative therapies.
Massad, L. Stewart, Powell, Matthew A, Wan, Leping, Zamorano, Abigail S   +3 more
core   +3 more sources

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials [PDF]

, 2015
Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.
BENEDETTI PANICI, PIERLUIGI, DE FELICE, FRANCESCA, DI DONATO, VIOLANTE, GASPARRI, MARIALUISA, Marchetti, C, MUSELLA, ANGELA, Musio, D, MUZII, LUDOVICO, PALAIA, INNOCENZA, TOMBOLINI, Vincenzo   +9 more
core   +1 more source

EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION

Тазовая хирургия и онкология, 2015
Purpose. To conduct retrospective analysis of treatment results of combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab use in Kirov ...
N. Z. Sherman, M. S. Ramazanova, Ye. N. Gopachenko   +2 more
doaj   +1 more source

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Cancer Medicine, 2023
Background BAT1706 is a proposed biosimilar of bevacizumab (Avastin®). We aimed to compare the efficacy and safety of BAT1706 with that of EU‐sourced reference bevacizumab (EU‐bevacizumab) in patients with advanced nonsquamous non‐small cell lung cancer (
Likun Chen, Jose David Gomez Rangel, Timucin Cil, Xingya Li, Irfan Cicin, Yihong Shen, Zhihua Liu, Ozgur Ozyilkan, Bondarenko Igor, Jun Chen, Kostiuk Oleksandr, Zhendong Chen, Helong Zhang, Ziyi Fu, Qingfeng Dong, Shuqiang Song, Jin‐Chen Yu, Li Zhang   +17 more
doaj   +1 more source

Bevacizumab (Avastin) [PDF]

American Journal of Neuroradiology, 2009
Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
openaire   +2 more sources

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer [PDF]

, 2013
Background: Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.
Arnold, Dirk, Dellas, Kathrin, Dunst, Jürgen, Engel, Erik, Höhler, Thomas, Reese, Thomas, Richter, Michael, Rödel, Claus, Wagner, Wolfgang, Würschmidt, Florian   +9 more
core   +1 more source

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series

Case Reports in Neurology, 2016
Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields ...
George Ansstas, David D. Tran
doaj   +1 more source

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab

Drugs in R&D, 2023
Background BAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several different cancers, including metastatic colorectal cancer. A comprehensive physicochemical and functional
Di Cao, Chunping Deng, Guangying Wang, Xiong Mei, Jianhua Xie, Yuanmei Liu, Yujie Liu, Yili Yang, Shengfeng Li, Cuihua Liu   +9 more
doaj   +1 more source

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. [PDF]

, 2017
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the
Aghi, MK, Castro, BA, Chen, W, De Lay, M, Flanigan, P, Hoffman, D, Jahangiri, A, Kohanbash, G, Kuang, R, Mascharak, S, Okada, H, Shrivastav, S, Sidorov, M, Wagner, JR, Yagnik, G   +14 more
core   +1 more source